Capricorn One

Capricor Therapeutics is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment of rare diseases. The company's lead candidate, deramiocel (CAP-1002), consists of allogeneic cardiosphere-derived cells and is currently in Phase 3 clinical trials for Duchenne muscular dystrophy (DMD). Capricor is also leveraging its proprietary StealthX exosome platform to develop a new class of biological therapeutics for vaccinology and targeted drug delivery. The company aims to address significant unmet medical needs in cardiac and genetic disorders through its innovative regenerative medicine approach.